M11.159 Familial chondrocalcinosis, unspecified hip

Name of the Condition

• Familial chondrocalcinosis, unspecified hip

Summary

Familial chondrocalcinosis, unspecified hip is a hereditary condition marked by the deposition of calcium pyrophosphate dihydrate (CPPD) crystals in the hip joint and surrounding tissues. This leads to inflammation, pain, and potential joint damage. It is a subtype of calcium pyrophosphate deposition disease (CPPD) with a genetic basis, specifically affecting the hip. Diagnosis typically involves clinical evaluation, imaging, and sometimes crystal identification in joint fluid or tissue.

Causes

Familial chondrocalcinosis, unspecified hip is caused by genetic mutations that influence calcium pyrophosphate crystal formation in the hip’s cartilage, synovium, or periarticular structures. These mutations may affect enzymes or proteins involved in crystal metabolism, leading to abnormal crystal deposition. The condition is inherited, though the exact genetic pathways vary.

Risk Factors

• Family history of chondrocalcinosis or related crystal arthropathies.
• Advanced age (increases likelihood of crystal deposition).
• Metabolic conditions affecting calcium or phosphate levels.
• Hip trauma or surgery (may trigger crystal release).
• Chronic inflammatory joint diseases.

Symptoms

• Hip pain, swelling, and stiffness.
• Recurrent episodes of acute inflammation.
• Reduced range of motion.

Diagnosis

Diagnosis of familial chondrocalcinosis, unspecified hip involves a combination of clinical assessment, imaging studies (e.g., X-rays, ultrasound, or MRI), and sometimes analysis of joint fluid or tissue to identify CPPD crystals. Clinical evaluation focuses on joint symptoms and family history, while imaging helps detect crystal deposits or joint damage. Crystal identification in synovial fluid confirms the diagnosis in ambiguous cases.

Treatment Options

Treatment aims to manage symptoms and reduce inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs) or colchicine may alleviate acute pain and swelling. Intra-articular corticosteroid injections can provide targeted relief. Physical therapy helps maintain joint function and mobility. For severe cases, surgical intervention (e.g., joint repair or replacement) may be considered.

Prognosis and Follow-Up

Prognosis varies based on the extent of joint damage and response to treatment. Early intervention can mitigate symptoms and slow progression, but chronic inflammation may lead to degenerative changes over time. Regular follow-up with a healthcare provider is recommended to monitor joint health, adjust treatments, and address complications.

Complications

Potential complications include chronic joint pain, reduced mobility, and progressive osteoarthritis due to ongoing crystal deposition and inflammation. Severe cases may result in joint deformity or disability if left untreated.

Lifestyle & Prevention

Lifestyle modifications, such as maintaining a healthy weight to reduce hip stress, engaging in low-impact exercise, and avoiding activities that strain the hip, may help manage symptoms. While genetic predisposition cannot be prevented, prompt treatment of acute episodes and regular monitoring can minimize long-term damage.

When to Seek Professional Help

Seek medical attention if hip pain is severe, persistent, or accompanied by swelling, stiffness, or reduced mobility. Acute episodes of inflammation or sudden worsening of symptoms warrant prompt evaluation to prevent joint damage.

Tips for Medical Coders

When coding for familial chondrocalcinosis, unspecified hip (M11.159), ensure documentation supports the hereditary nature of the condition and hip involvement. Verify that the hip is not specified as left or right, as this code applies to unspecified hip. Confirm absence of additional details (e.g., bilateral or specific joint involvement) that would require a more precise code.